Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 47.96 0.00% 0.00
PTLA closed unchanged on Friday, February 16, 2018, on 34 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Earnings due: Feb 28

5 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical PTLA trend table...

Date Alert Name Type % Chg
Feb 16 Shooting Star Candlestick Bearish 0.00%
Feb 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Feb 16 Doji - Bearish? Reversal 0.00%
Feb 16 Wide Bands Range Expansion 0.00%
Feb 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Feb 15 Narrow Range Bar Range Contraction 0.00%
Feb 15 NR7 Range Contraction 0.00%
Feb 15 Wide Bands Range Expansion 0.00%
Feb 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.48%
Feb 14 Outside Day Range Expansion 1.48%

Older signals for PTLA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 67.1
52 Week Low 29.5
Average Volume 966,709
200-Day Moving Average 50.9913
50-Day Moving Average 49.8462
20-Day Moving Average 49.181
10-Day Moving Average 46.557
Average True Range 2.5371
ADX 19.41
+DI 21.0
-DI 28.38
Chandelier Exit (Long, 3 ATRs ) 47.8687
Chandelier Exit (Short, 3 ATRs ) 48.9813
Upper Bollinger Band 55.18
Lower Bollinger Band 43.182
Percent B (%b) 0.4
BandWidth 24.3956
MACD Line -1.0366
MACD Signal Line -0.8898
MACD Histogram -0.1468
Fundamentals Value
Market Cap 2.76 Billion
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -10.54
Price-to-Sales 85.78
Price-to-Book 24.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 50.38
Resistance 3 (R3) 50.48 49.79 49.97
Resistance 2 (R2) 49.79 49.17 49.73 49.84
Resistance 1 (R1) 48.87 48.79 49.33 48.77 49.70
Pivot Point 48.18 48.18 48.41 48.12 48.18
Support 1 (S1) 47.26 47.56 47.72 47.16 46.22
Support 2 (S2) 46.57 47.18 46.51 46.08
Support 3 (S3) 45.65 46.57 45.95
Support 4 (S4) 45.55